Asia Deep Research (21)
21 papers in the Asia Deep topic, indexed by PF-Atlas from PubMed and global journals.
- Comparing survival outcomes of anti-fibrotic therapy for idiopathic pulmonary fibrosis with and without emphysema: a multi-center real-world study from Taiwan · BMC Pulmonary Medicine · 2025
- Oral Antifibrotic Agents for the Treatment of Idiopathic Pulmonary Fibrosis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials · Journal of Clinical Question · 2025
- Taladegib for the treatment of idiopathic pulmonary fibrosis : a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial. · The Lancet. Respiratory medicine · 2025
- Rickets prevalence and treatment outcome: real-world data from Taiwan · Clinical and Experimental Pediatrics · 2025
- Association between initial treatment response and prognosis in acute exacerbations of idiopathic pulmonary fibrosis treated with steroid pulse therapy. · Respiratory medicine · 2025
- Nintedanib and Pirfenidone Treatment Outcome Comparisons in Idiopathic Pulmonary Fibrosis Patients · American Journal of Respiratory and Critical Care Medicine · 2025
- Identifying outcome domains to establish a core outcome set for progressive pulmonary fibrosis: a scoping review · European Respiratory Review · 2025
- Inhalable myofibroblast targeting nanoparticles for synergistic treatment of pulmonary fibrosis · Science Advances · 2025
- Adverse side-effects of antifibrotic drugs and outcome of treatment in idiopathic pulmonary fibrosis · Journal of Thoracic Disease · 2025
- Quantitative HRCT as a surrogate outcome measure for nintedanib treatment in systemic sclerosis-interstitial lung disease and idiopathic pulmonary fibrosis. · Joint bone spine · 2025
- Differential Effects of Antifibrotic Treatment on Outcome Prediction via Serial Matrix Metalloproteinase-Degraded C-Reactive Protein Neoepitope Levels in Idiopathic Pulmonary Fibrosis · Chest · 2025
- Donor age over 55 is associated with worse outcome in lung transplant recipients with idiopathic pulmonary fibrosis · BMC Pulmonary Medicine · 2024
- Treating sleep-disordered breathing of idiopathic pulmonary fibrosis patients with CPAP and nocturnal oxygen treatment. A pilot study · Respiratory Research · 2024
- Microbial community organization designates distinct pulmonary exacerbation types and predicts treatment outcome in cystic fibrosis · Research Square · 2024
- Progressive pulmonary fibrosis : Estimation of incidence and treatment rates in Japan using a claims database. · Respiratory investigation · 2024
- Construction of the pulmonary bio-adhesive delivery system of nintedanib nanocrystalline for effective treatment of pulmonary fibrosis. · International journal of pharmaceutics · 2024
- Microbial community organization designates distinct pulmonary exacerbation types and predicts treatment outcome in cystic fibrosis · Nature Communications · 2024
- Risk of potential hepatotoxicity from pirfenidone or nintedanib in patients with idiopathic pulmonary fibrosis: results of a retrospective analysis of a large insurance database in Taiwan · Frontiers in Pharmacology · 2024
- Real-World Experience in the Clinical Use of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Taiwan: A Post-Marketing Surveillance Study · Biomedicines · 2024
- Real world experience on the effectiveness and safety of pirfenidone in patients with idiopathic pulmonary fibrosis in Taiwan · Frontiers in Medicine · 2023
- Microbial community organization designates distinct pulmonary exacerbation types and predicts treatment outcome in cystic fibrosis · bioRxiv · 2023
Medical disclaimer. Research listings are for information only and are not medical advice.